Clinical Trial Update: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SNP-610 for treating nonalcoholic steatohepatitis (NASH). Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• SNP-610

Snippet

Sponsor: Sinew Pharma Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: NOT_YET_RECRUITING